Is PLRX or TENX more profitable?

Tenax Therapeutics' return on equity of -56.32% beat Pliant Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pliant Therapeutics N/A -58.11% -44.37% Tenax Therapeutics N/A -56.32% -53.12%

Is ELDN or PLRX more profitable?

Pliant Therapeutics' return on equity of -58.11% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eledon Pharmaceuticals N/A -116.97% -41.91% Pliant Therapeutics N/A -58.11% -44.37%

Does the media prefer ELDN or PLRX?

In the previous week, Eledon Pharmaceuticals had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 3 mentions for Eledon Pharmaceuticals and 2 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.93 beat Eledon Pharmaceuticals' score of 0.84 indicating that Pliant Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pliant Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NAGE or PLRX?

In the previous week, Niagen Bioscience and Niagen Bioscience both had 2 articles in the media. Niagen Bioscience's average media sentiment score of 0.93 equaled Pliant Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Niagen Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pliant Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IMRX or PLRX more profitable?

Immuneering's return on equity of -31.93% beat Pliant Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -31.93% -29.92% Pliant Therapeutics N/A -58.11% -44.37%

Does the media prefer IMRX or PLRX?

In the previous week, Immuneering had 4 more articles in the media than Pliant Therapeutics. MarketBeat recorded 6 mentions for Immuneering and 2 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.93 beat Immuneering's score of 0.86 indicating that Pliant Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Pliant Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Pliant Therapeutics (PLRX) Competitors

$1.14 +0.01 (+0.44%)

As of 12:03 PM Eastern

Compare

PLRX vs. BCYC, TENX, ELDN, NAGE, and IMRX

Should you buy Pliant Therapeutics stock or one of its competitors? MarketBeat compares Pliant Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pliant Therapeutics include Bicycle Therapeutics (BCYC), Tenax Therapeutics (TENX), Eledon Pharmaceuticals (ELDN), Niagen Bioscience (NAGE), and Immuneering (IMRX). These companies are all part of the "pharmaceutical products" industry.

How does Pliant Therapeutics compare to Bicycle Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 8.5% of Bicycle Therapeutics shares are owned by insiders. Comparatively, 6.4% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bicycle Therapeutics has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

Pliant Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -344.95%. Bicycle Therapeutics' return on equity of -35.74% beat Pliant Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
Pliant Therapeutics	N/A	-58.11%	-44.37%

Bicycle Therapeutics currently has a consensus price target of $14.00, indicating a potential upside of 246.45%. Pliant Therapeutics has a consensus price target of $3.00, indicating a potential upside of 164.32%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Bicycle Therapeutics is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, Pliant Therapeutics had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 2 mentions for Pliant Therapeutics and 1 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 1.87 beat Pliant Therapeutics' score of 0.93 indicating that Bicycle Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Bicycle Therapeutics	Very Positive
Pliant Therapeutics	Positive

Pliant Therapeutics has lower revenue, but higher earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	3.87	-$218.96M	-$3.15	N/A
Pliant Therapeutics	$1.58M	44.48	-$149.34M	-$1.84	N/A

Summary

Bicycle Therapeutics beats Pliant Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Pliant Therapeutics compare to Tenax Therapeutics?

Pliant Therapeutics (NASDAQ:PLRX) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Pliant Therapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

Tenax Therapeutics' return on equity of -56.32% beat Pliant Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-58.11%	-44.37%
Tenax Therapeutics	N/A	-56.32%	-53.12%

In the previous week, Pliant Therapeutics and Pliant Therapeutics both had 2 articles in the media. Tenax Therapeutics' average media sentiment score of 1.43 beat Pliant Therapeutics' score of 0.93 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Pliant Therapeutics	Positive
Tenax Therapeutics	Positive

97.3% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 6.4% of Pliant Therapeutics shares are held by company insiders. Comparatively, 3.7% of Tenax Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Tenax Therapeutics has lower revenue, but higher earnings than Pliant Therapeutics. Tenax Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58M	44.48	-$149.34M	-$1.84	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A

Pliant Therapeutics currently has a consensus target price of $3.00, indicating a potential upside of 164.32%. Tenax Therapeutics has a consensus target price of $39.67, indicating a potential upside of 253.22%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenax Therapeutics is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Tenax Therapeutics beats Pliant Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Pliant Therapeutics compare to Eledon Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Pliant Therapeutics' return on equity of -58.11% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
Pliant Therapeutics	N/A	-58.11%	-44.37%

In the previous week, Eledon Pharmaceuticals had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 3 mentions for Eledon Pharmaceuticals and 2 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.93 beat Eledon Pharmaceuticals' score of 0.84 indicating that Pliant Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pliant Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eledon Pharmaceuticals has higher earnings, but lower revenue than Pliant Therapeutics. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
Pliant Therapeutics	$1.58M	44.48	-$149.34M	-$1.84	N/A

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 9.6% of Eledon Pharmaceuticals shares are held by company insiders. Comparatively, 6.4% of Pliant Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Eledon Pharmaceuticals currently has a consensus target price of $9.67, indicating a potential upside of 174.23%. Pliant Therapeutics has a consensus target price of $3.00, indicating a potential upside of 164.32%. Given Eledon Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Eledon Pharmaceuticals is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Eledon Pharmaceuticals has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

Summary

Eledon Pharmaceuticals beats Pliant Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Pliant Therapeutics compare to Niagen Bioscience?

Niagen Bioscience (NASDAQ:NAGE) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Niagen Bioscience has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

Niagen Bioscience has higher revenue and earnings than Pliant Therapeutics. Pliant Therapeutics is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	2.15	$17.38M	$0.21	16.64
Pliant Therapeutics	$1.58M	44.48	-$149.34M	-$1.84	N/A

In the previous week, Niagen Bioscience and Niagen Bioscience both had 2 articles in the media. Niagen Bioscience's average media sentiment score of 0.93 equaled Pliant Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Niagen Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pliant Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Niagen Bioscience has a net margin of 14.29% compared to Pliant Therapeutics' net margin of 0.00%. Niagen Bioscience's return on equity of 22.68% beat Pliant Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	14.29%	22.68%	16.23%
Pliant Therapeutics	N/A	-58.11%	-44.37%

15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by insiders. Comparatively, 6.4% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Niagen Bioscience presently has a consensus price target of $10.50, suggesting a potential upside of 200.43%. Pliant Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 164.32%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, research analysts plainly believe Niagen Bioscience is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Niagen Bioscience beats Pliant Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Pliant Therapeutics compare to Immuneering?

Immuneering (NASDAQ:IMRX) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, Immuneering had 4 more articles in the media than Pliant Therapeutics. MarketBeat recorded 6 mentions for Immuneering and 2 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.93 beat Immuneering's score of 0.86 indicating that Pliant Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Pliant Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immuneering's return on equity of -31.93% beat Pliant Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-31.93%	-29.92%
Pliant Therapeutics	N/A	-58.11%	-44.37%

Immuneering presently has a consensus price target of $16.50, suggesting a potential upside of 285.96%. Pliant Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 164.32%. Given Immuneering's stronger consensus rating and higher possible upside, research analysts clearly believe Immuneering is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

67.7% of Immuneering shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 22.9% of Immuneering shares are owned by insiders. Comparatively, 6.4% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Immuneering has higher earnings, but lower revenue than Pliant Therapeutics. Immuneering is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A
Pliant Therapeutics	$1.58M	44.48	-$149.34M	-$1.84	N/A

Immuneering has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Summary

Immuneering beats Pliant Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Pliant Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLRX vs. The Competition

Export

Metric	Pliant Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$70.28M	$3.40B	$6.50B	$12.32B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-0.62	20.12	24.00	24.65
Price / Sales	44.48	326.92	543.88	171.03
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	0.38	8.09	10.73	6.84
Net Income	-$149.34M	$23.89M	$3.56B	$337.45M
7 Day Performance	-1.30%	3.15%	1.34%	2.48%
1 Month Performance	-1.30%	1.14%	2.25%	4.36%
1 Year Performance	-17.75%	46.12%	26.20%	32.45%

Pliant Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLRX Pliant Therapeutics	2.2253 of 5 stars	$1.14 +0.4%	$3.00 +164.3%	-18.1%	$70.28M	$1.58M	N/A	90	Gap Up
BCYC Bicycle Therapeutics	3.769 of 5 stars	$4.15 -1.2%	$14.00 +237.4%	-51.6%	$288.32M	$72.86M	N/A	240
TENX Tenax Therapeutics	3.0837 of 5 stars	$10.75 +2.0%	$29.67 +176.0%	+101.4%	$285.12M	N/A	N/A	9	Positive News Analyst Forecast
ELDN Eledon Pharmaceuticals	1.7558 of 5 stars	$3.67 +2.4%	$9.67 +163.8%	+24.4%	$282.90M	N/A	N/A	10
NAGE Niagen Bioscience	4.3402 of 5 stars	$3.45 +2.5%	$10.50 +204.0%	-74.7%	$272.85M	$129.42M	16.31	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLRX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pliant Therapeutics (PLRX) Competitors

PLRX vs. BCYC, TENX, ELDN, NAGE, and IMRX

How does Pliant Therapeutics compare to Bicycle Therapeutics?

Summary

How does Pliant Therapeutics compare to Tenax Therapeutics?

Summary

How does Pliant Therapeutics compare to Eledon Pharmaceuticals?

Summary

How does Pliant Therapeutics compare to Niagen Bioscience?

Summary

How does Pliant Therapeutics compare to Immuneering?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX vs. The Competition

Pliant Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pliant Therapeutics (PLRX) Competitors

PLRX vs. BCYC, TENX, ELDN, NAGE, and IMRX

How does Pliant Therapeutics compare to Bicycle Therapeutics?

Do insiders & institutionals have more ownership in BCYC or PLRX?

Which has more volatility and risk, BCYC or PLRX?

Is BCYC or PLRX more profitable?

Do analysts rate BCYC or PLRX?

Does the media favor BCYC or PLRX?

Which has better earnings & valuation, BCYC or PLRX?

Summary

How does Pliant Therapeutics compare to Tenax Therapeutics?

Which has more risk & volatility, PLRX or TENX?

Is PLRX or TENX more profitable?

Does the media prefer PLRX or TENX?

Do insiders and institutionals have more ownership in PLRX or TENX?

Which has better valuation & earnings, PLRX or TENX?

Do analysts recommend PLRX or TENX?

Summary

How does Pliant Therapeutics compare to Eledon Pharmaceuticals?

Is ELDN or PLRX more profitable?

Does the media prefer ELDN or PLRX?

Which has preferable valuation and earnings, ELDN or PLRX?

Do institutionals and insiders have more ownership in ELDN or PLRX?

Do analysts recommend ELDN or PLRX?

Which has more volatility and risk, ELDN or PLRX?

Summary

How does Pliant Therapeutics compare to Niagen Bioscience?

Which has more risk & volatility, NAGE or PLRX?

Which has preferable valuation & earnings, NAGE or PLRX?

Does the media prefer NAGE or PLRX?

Is NAGE or PLRX more profitable?

Do insiders and institutionals hold more shares of NAGE or PLRX?

Do analysts recommend NAGE or PLRX?

Summary

How does Pliant Therapeutics compare to Immuneering?

Does the media prefer IMRX or PLRX?

Is IMRX or PLRX more profitable?

Do analysts rate IMRX or PLRX?

Do institutionals and insiders hold more shares of IMRX or PLRX?

Which has better valuation & earnings, IMRX or PLRX?

Which has more volatility & risk, IMRX or PLRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX vs. The Competition

Pliant Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools